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Cytotoxic T  lymphocytes (CTL) reactive with human mela­
noma tumor cells occasionally display cross-reactivity with 
normal melanocytes. Previously, we identified the melanocyte 
lineage-specific antigen gp 100 that is expressed by both mela­
noma cells and normal melanocytes, as a target antigen for 
tumor-infiltrating lymphocytes derived from a melanoma pa­
tient (TIL 1200). Here, we demonstrate that the oligoclonal 
HLA-A2.1-restricted TIL 1200 line is reactive with 2 distinct 
peptides derived from the gplOO protein. Apart from the 
peptide corresponding to gplOO amino acids 457—466, we 
identified the gplOO peptide E54-162 as a second epitope 
recognized by TIL 1200. A  100-fold lower concentration of this 
novel gplOO peptide was required for target-cell sensitization 
compared to peptide 457-466, indicating that the 154-162 
peptide is the dominant gplOO epitope for TIL 1200. Together 
with the recently described gplOO 280-288 epitope, 3 distinct 
CTL epitopes have now been identified in gplOO, all presented 
in the context of HLA-A2.1. Therefore, gplOO is an attractive 
target antigen in the development of immuno-therapeutic 
protocols against melanoma.
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CTL that recognize melanoma tumor cells in a T-cell- 
receptor (TcR)-mediated and MHC-restricted manner have 
been isolated from tumor-bearing patients (for a review see 
Knuth et al, 1992). However, the identity of the antigens and 
epitopes recognized by anti-melanoma CTL remains largely 
unknown. These CTL often display cross-reactivity with alloge­
neic HLA-A2.1 matched melanomas, implying that shared 
melanoma antigens are recognized in the context of HLA-A2.1 
(Darrow et ai, 1989; Kawakami et al, 1992), Recently, it has 
been reported that some CTL react not only with melanoma 
tumor cells but also with normal melanocytes, suggesting 
recognition of melanocyte differentiation antigens (Anichini et 
al, 1993).
Using a genetic approach, Boon and colleagues have suc­
ceeded in identifying a number of antigens recognized by 
anti-melanoma CTL. Apart from the tumor-specific MAGE-1 
and -3 antigens (Van der Bruggen et al, 1991; Gaugler et al, 
1994), they also identified the melanocyte lineage-specific 
tyrosinase protein as a target for melanoma-specific CTL 
(Brichard et al, 1993). Similarly, we have identified the gplOO 
melanocyte-specific protein as a target antigen for melanoma 
tumor-infiltrating lymphocytes (TIL) (Bakker et al, 1994). 
Recently, another melanocyte differentiation antigen, Melan 
A/MART-1, was identified as a target for anti-melanoma CTL 
(Coulie e ta l ,  1994; Kawakami et al, 1994a). Collectively, these 
findings demonstrate that melanocyte differentiation antigens 
can be immunogenic.
The gplOO antigen is an intracellular glycoprotein of approxi­
mately 100 kDa and is recognized by MAb NKI-beteb (Venne- 
goor et al, 1988). Expression of gplOO is restricted to cells of 
the melanocytic lineage. Recently, we isolated a cDNA clone 
encoding gplOO (Adema et al, 1993). Characterization of the 
gplOO cDNA revealed that gplOO is a type-I transmembrane 
glycoprotein highly homologous to another melanocyte-
specific protein, Pmell7 (Adema et al, 1994). Introduction of 
the gplOO encoding cDNA into gp 100-negative BLM cells 
conferred susceptibility to lysis by tumor-infiltrating lympho­
cytes derived from a melanoma patient (TIL 1200) (Bakker et 
al, 1994). Furthermore, short-term cultures of HLA-A2.1+ 
normal melanocytes were also Iysed by TIL 1200, demonstrat­
ing that TIL 1200 recognizes the non-mutated gplOO protein.
Recently, it has been demonstrated that a naturally pro­
cessed gplOO peptide (amino acids 280-288) that was identi­
fied by tandem mass spectroscopy, could direct target-cell lysis 
by HLA-A2.1+ restricted anti-melanoma CTL lines (Cox et al, 
1994). We have shown that TIL 1200 is reactive with the gplOO 
peptide 457-466 in the context of HLA-A2.1 (Kawakami et al, 
1994b). Here, we report the identification of a novel HLA-A2.1- 
presented gplOO peptide, corresponding to amino acids 154— 
162, as the dominant epitope recognized by the oligoclonal 
TIL 1200 line.
M A TERIA L A N D  M ETH O D S
Cell culture
TIL 1200 lymphocytes were isolated from metastatic mela­
noma and were grown as was described previously (Kawakami 
et a l j  1992). HLA-A2.1+ melanoma lines BLM and BLM 
gplOO H2.3 were cultured as described previously (Bakker et 
al, 1994), COS-7 cells were grown in DMEM (GIBCO, 
Paisley, UK) supplemented with 7.5% FCS. TAP-deficient 
TxB cell hybrid T2 cells (Salter et al, 1985) were maintained in 
Iscove’s medium (GIBCO) +1.5%  FCS.
Peptides
Peptides were synthesized with a free carboxy-terminus 
either by f-moc peptide chemistry using an ABIMED Multiple 
Synthesizer 422 (Abimed, Langenfeld, Germany) or by t-boc 
chemistry on a Biosearch 9500 peptide synthesizer (New 
Brunswick, San Rafael, CA). Peptides were dissolved in 
DMSO and stored at —20°C.
DNA constmction and transfection
Isolation of the gplOO cDNA clone cl has been described 
elsewhere (Adema e ta l,  1993). The gplOO cDNA was inserted 
into expression vectors pBJlneo (Lin et al, 1990), pCMVneo 
(Baker et al, 1990) and pSVL (Pharmacia, Woerden, The 
Netherlands). To generate a gplOO cDNA lacking the coding 
sequences for the peptide 457-466, PCR reactions were 
performed with the following combinations of oligonucleo-
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tides: 5'-CATGGAAGTGACTGTCTACC-3' /5 '-CTGAGC- 
GAATTCGGAACCTGTAATACTTTCCG-3' and 5'-CT- 
G AGCGAATTCGTGAAG AG ACAAGTCCCCC-3' 15 ' - 
TCACAGCATCATATGAGAGTAC-3' using the full-length 
gplOO cDNA as a template. PCR products were digested with 
Eco RI, ligated and served as a template for a nested PCR 
using the following primers: 5'-GCACAGGCCAACTGCAGA- 
3V5r-TTC AGTATCTGGTGCAGAAC-3'. The Kpn I-Cla I 
fragment from this PCR product was then replaced by the 
corresponding fragment in pCMVgplOOneo to generate 
pCMVgpl00DEL454-481neo. GplOO cDNA mutants DEL149- 
661 and DEL454-661 were obtained by deletion of the 1.7-kb 
Hind III and the 0.8-kb Eco RI fragments from 
pBJlgpl00DEL454-481neo respectively. GplOO cDNA mu­
tants DEL100-661, DEL194-528 and DEL167-508 were ob­
tained by deletion of the Bgl I-Sac I, Bam HI-Bgl II and Apa 
I-Nsi I fragments from pSVLgplOO respectively.
BLM ceils were transfected with 20 (jug of pCMV- 
gpl00DEL454-481neo DNA according to the calcium phos­
phate co-precipitation procedure (Graham and van der Eb, 
1973) using calcium phosphate transfection systems (BRL, 
Gaithersburg, MD) and were selected with 1 mg/ml G418 
(GIBCO).
COS-7 cells were co-transfected with 5 \xg of pBJlHLA- 
A2.1neo and 5 |xg of pBJl or pSVL plasmids containing either 
full-length or deleted gplOO cDNAs using the DEAE-dextran/ 
chloroquine method (Seed and Aruffo, 1987) (the HLA-A2 / 1  
cDNA was kindly provided by J.J. Neefjes, The Netherlands 
Cancer Institute, Division of Biochemistry, Amsterdam, The 
Netherlands). After 48 hr of transfection, COS-7 cells were 
used as stimulator cells in IFN7  release experiments,
Chromium-release assay
Chromium-release assays were performed as described pre­
viously (Bakker et al, 1994), Briefly, 106 target cells were
incubated with 100 jxCi Na^QCU (Amersham, Aylesbury, 
UK) for 1 hr. Various amounts of effector cells were then 
added to 2 x 103 target cells in triplicate wells of U-bottomed 
microtiter plates (Costar, Badhoevedorp, The Netherlands) in 
a final volume of 150 jil. In peptide recognition assays, target 
cells were pre-incubated with various amounts of peptide for 
90 min at 37°C in a volume of 50 |xl prior to the addition of 
effector cells. After 5 hr of incubation, part of the supernatant 
was harvested and its radioactive content was measured.
conjugated GAM-IgG-F(ab ' ) 2 (Zymed, San Francisco, CA) 
was used for the second incubation.
IFNy-release assay
TIL 1200 responder cells (105) were incubated together with 
5 x 104 transiently transfected COS-7 stimulator cells in 300 |xl 
medium in the presence of 100 U/ml IL-2 in a flat-bottomed 
96-well microtiter plate. After 24 hr of incubation, 100 |±1 of 
supernatant were harvested and screened for the presence of 
IFN7  using an hlFNy-IRMA immunoradiometric assay kit 
(Medgenix, Fleurus, Belgium).
HLA-A2.1 stabilization on T2 ceils
Peptide-induced HLA-A2.1 stabilization on T2 cells was 
performed as described previously (Nijman et al, 1993). 
Briefly, peptides were diluted from DMSO stocks to 50,25 and 
12.5 |xg/ml (final DMSO concentration 0.5%) and incubated 
together with 105 T2 cells for 14 hr at 37°C, 5% C 0 2 in 
serum-free Iscove’s medium in a volume of 100 |xl in the 
presence of 3 [xg/ml human p2-microglobulin (Sigma, St Louis, 
MO). Stabilization of HLA-A2.1 molecules at the surface of 
T2 cells was analyzed by flow cytometry using a FACScan flow 
cytometer (Becton Dickinson, Mountain View, CA). Anti- 
HLA-A2 MAb BB7.2 (culture supernatant) (Parham and 
Brodsky, 1981) was used as a primary reagent. FITC-
RESULTS
TIL 1200 is reactive with more than one peptide derived 
from gplOO
To determine the nominal gplOO epitope being recognized 
by TIL 1200, a number of gp 100-derived peptides were 
synthesized according to the HLA-A2 .1  binding motifs (Falk et 
al, 1991; Hunt et al, 1992; Ruppert et al, 1993) and tested for 
their ability to sensitize target cells (Kawakami et al, 19946). 
Only one of these peptides, corresponding to amino acids 
457-466, was able to induce target-cell lysis by TIL 1200. 
However, when this peptide was used in chromium-release 
assays (Fig. 1 ), we observed only a low percentage of specific 
release (20-25%), Furthermore, a relatively high concentra­
tion of peptide ( ~  1 0 0  ng/ml) was needed to induce target-cell 
lysis by TIL 1200. We therefore questioned whether other 
gplOO-derived peptides could be recognized by TIL 1200, a 
TIL line that was found to be oligoclonal when analyzed at the 
T-cell receptor (TcR) level (Shilyanski et al, 1994).
A putative second gplOO peptide which was a candidate for 
recognition by TIL 1200, was peptide 280-288. This naturally 
processed peptide was identified using tandem mass spectros­
copy and found to be recognized with high affinity by 5 
melanoma-specific CTL lines (Cox et al, 1994). We tested this 
peptide for recognition by TIL 1200 but did not observe any 
reactivity (data not shown).
To address the question whether TIL 1200 might recognize 
another peptide derived from gplOO, we constructed a mutant 
gplOO cDNA. The resulting construct, pBJl-gpl00DEL454- 
481neo, encodes a protein in which the 457-466 peptide is 
absent. We transfected human HLA-A2.1 + gplOO- BLM 
melanoma cells with pBJl-gpl00DEL454-481neo DNA. Subse­
quently, G418-resistant BLM gplOO DEL454-4S1 clones were 
screened for expression of mutated gplOO using MAb NKI- 
beteb and tested in chromium-release assays using TIL 1200. 
As shown in Figure 2, elimination of the 457-466 epitope did
peptide concentration ([¿g/ml)
F ig u r e  1 — TIL 1200 recognizes the gplOO 457-466 peptide. 
Chromium-labelled T2 target cells were pre-incubated for 90 min 
with various amounts of peptide. TIL 1200 lymphocytes were 
added at an effector to target ratio of 30:1. After 5 hr of 
incubation, chromium release was measured. Peptide 96-105 is an 
irrelevant gplOO-derived peptide that binds to HLA-A2.1. Pep­
tides: 0 —0 ,  gplOO 96-105; gplOO 457-466.
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E/T ratio
F ig u r e  2  -  TIL 1200 recognizes more than one epitope derived 
from gplOO. HLA-A2.1+ BLM melanoma cells were used as target 
cells. BLM gplOO transfectants that do (H2.3) or do not express 
the gplOO 457-466 epitope (DEL 454-481IIA1/ID5) were recog­
nized by TIL 1200. Targets: 0 —0 , BLM; BLM gplOO 
H2.3; A—▲, BLM gplOO DEL454-481 IIA1; BLM gplOO 
DEL454-481ID5.
not abolish TIL 1200 reactivity: BLM gplOO DEL454-481 
clones were efficiently lysed. We therefore conclude that the 
TIL 1200 line recognizes more than one epitope derived from 
gplOO.
GplOO peptide 154-162 is the second gplOO epitope recognized 
by TIL 1200
Subsequently, to define the region of the gplOO protein that 
contains the unknown second epitope, a number of different 
gplOO cDNA deletion mutants were generated that all lacked 
the sequence encoding the 457-466 epitope (Fig. 3). These 
mutant gplOO cDNAs, cloned into the expression vectors 
pBJl-neo or pSVL, were transfected into COS-7 cells together 
with an expression vector carrying the HLA-A2.1 cDNA. 
These COS-7 transfectants were then tested for their ability to 
induce IFN7  secretion by TIL 1200 upon TcR engagement.
As shown in Figure 3, TIL 1200 specifically secreted IFNy 
when stimulated with COS-7 cells transfected with HLA-A2.1 
and the full-length gplOO cDNA. In accordance with the 
cytotoxicity data (Fig. 2), we again observed TIL 1200 reactiv­
ity against the gplOO DEL454-481 mutant that does not 
encode the 457-466 epitope. From the other gplOO deletion 
mutants, only the DEL100-661 and DEL149-661 constructs 
were not recognized, thereby excluding the possibility that TIL 
1200 was reactive with a peptide located N-terminal from 
amino-acid position 148 in the gplOO protein. We could also 
exclude the C-terminal region of the gplOO protein, because 
we observed TIL 1200 reactivity using a mutant construct, 
DEL454-661, encoding the first 453 amino acids of gplOO. The 
observation that a construct encoding the N-terminal region 
up to amino acid 166 was able to stimulate TIL 1200 (DELI 67- 
508), demonstrated that a presumptive second epitope was 
localized between amino acids 148-166 of the gplOO protein.
Several motifs have been described for 9-mer to 10-mer 
peptides binding to HLA-A2.1, that were deduced from 
naturally processed and synthetic HLA-A2.1 binding peptides 
(Falk et al, 1991; Hunt et al, 1992; Ruppert et al, 1993). When 
these motifs were applied to the 148-166 region of the gplOO 
protein, no putative HLA-A2.1-binding peptides were found.
We therefore screened the 148-166 region of the gplOO 
protein for peptides that fitted into a less strict motif, including 
threonine residues at position 2. Using such a motif, a number 
of potential HLA-A2.1 binding peptides from the gplOO 
148-166 region were synthesized. These peptides were loaded 
onto HLA-A2.1+ T2 cells and tested for their ability to induce 
TIL-1200-mediated target-cell lysis (Fig. 4). The 5 peptides 
tested were all able to sensitize T2 cells for lysis by TIL 1200 
when applied at a concentration of 10 p-g/ml. All these 
peptides contain the 8 -mer peptide TWGQYWQV, corre­
sponding to gplOO amino acids 155-162. Next, all peptides 
were titrated to evaluate their relative ability to sensitize T2 
target cells for lysis by TIL 1200. Figure 4 shows that the 9-mer 
peptide KTWGQYWQV elicited 50% of maximal specific lysis 
by TIL 1200 when applied at a concentration of 3 ng/ml, 
whereas the other peptides had to be applied at higher 
concentrations. Therefore, the 9-mer 154-162 peptide is most 
likely the naturally processed second gplOO epitope that is 
recognized by TIL 1 2 0 0 .
Binding of gplOO epitopes 154-162} 280-288 
and 457-466 to HLA-A2.1
We compared the gplOO 155-162 and 457-466 epitopes, that 
are recognized by TIL 1200, to the above-mentioned gplOO 
280-288 peptide and 2  known viral epitopes presented in 
HLA-A2.1: the influenza matrix 58-66 peptide (Gotch et al, 
1987) and the HIV polymerase 510-518 peptide (Tsomides et 
al., 1991). We analyzed the HLA-A2.1 binding capacity of the 
different gplOO epitopes by means of an indirect binding assay 
using the processing-defective cell line T2 (Nijman et al,
1993), With this assay, we observed similar HLA-A2.1 stabili­
zation with the gplOO 280-288 epitope and the tested viral 
epitopes (Fig. 5). Both the 154-162 and 457-466 gplOO 
epitopes bind to HLA-A2.1 with a low affinity compared to the 
gplOO 280-288 eptiope and the viral epitopes, From these data 
we conclude that the gplOO epitopes bind to HLA-A2.1 with 
distinct affinities.
DISCUSSION
In the present report, we describe the identification of a 
novel gplOO epitope, corresponding to gplOO amino acids 
154-162, that is presented to anti-melanoma CTL in the 
context of HLA-A2.1. We show that the gplOO-reactive TIL 
1200 line, consisting of several TcR specificities (Shilyanski et 
al, 1994), recognizes not only the gplOO 457-466 epitope, but 
also the gplOO 154-162 epitope. HLA-A2.1 binding experi­
ments revealed that the gplOO 154-162 epitope and the gplOO 
457-466 epitope bind with relatively low affinity to HLA-A2.1, 
compared to the recently reported gplOO 280-288 epitope 
(Cox et al, 1994) and HLA-A2.1 restricted viral epitopes. This 
may be partly explained by the amino-acid composition of the 
gplOO epitopes recognized by TIL 1200. The lower affinity for 
HLA-A2.1 of peptide 457-466 may be due to the charged 
residues at positions 3 and 9 (Ruppert et al, 1993). Inefficient 
binding of the gplOO 154-162 epitope to HLA-A2.1 may be 
caused by the presence of a threonine residue at the N- 
terminal anchor position since, in most HLA-A2.1 binding 
peptides, leucine or methionine residues are present at this 
site. While both peptides bind to HLA-A2.1 with low affinity, a 
100-fold lower concentration of gplOO peptide 154-162 was 
required for the sensitization of T2 target cells for lysis by TIL 
1200, when compared to gplOO peptide 457-466. We therefore 
consider the 154-162 peptide to be the dominant gplOO 
epitope recognized by TIL 1200. Attempts to further investi­
gate the recognition of the different gplOO epitopes using
gp100 cDNA constructs
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F ig u r e  3 -  TIL 1200 recognizes a second gplOO-derived epitope located between amino acids !49 and 166. GplOO cDNA deletion 
mutants encoding parts of the gplOO protein were cloned into expression vectors and transfected into COS-7 along with the HLA-A2.1 
cDNA (numbers indicate amino acids in the gplOQ protein, amino acid 1 refers to the methionine in the signal peptide). TIL 1200 
lymphocytes and transfected COS-7 cells were co-incubated for 24 hr and the amount of IFN7  in the supernatant was measured using an 
immunoradiometric assay.
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F igure  4 -  TIL 1.200 predominantly recognizes the gplOO 154- 
162 epitope. Chromium release experiments were performed as in 
Figure 1. Five peptides derived from the gplOO 148-166 region, 
varying from an 8 -mer to an 1 1-mer, were tested for recognition by 
TIL 1200. T2 target cells were pre-incubated with various concen­
trations of peptide and specific lysis was determined at an effector 
to target ratio of 30:1. Peptides: VWKTWGQYWQV, ■ —■; 
KTWGQYWQVL, KTWGQYWQV, TWGQY-
WQVL, 0 —0 ; TWGQYWQV, A—A,
cloned TIL have not been successful. Since other anti-gplOO 
CTL-lines (Cox at ai, 1994) recognize the gplOO 280-288 
epitope, it remains to be established which epitope is immuno­
dominant in gplOO.
It is surprising that, in a single patient, anti-melanoma CTL 
have emerged that are reactive with 2  distinct epitopes derived 
from gplOO, a self antigen. The gplOO epitopes are recognized 
by at least 2 T-cell specificities, co-existing within the TIL 1200 












F ig u r e  5 -Binding of gplOO epitopes to HLA-A2.1. T2 cells 
were incubated with various concentrations of the gplOO 154-162, 
280-288 and 457-466 epitopes or with 2 HLA-A2.1 presentable 
viral epitopes. HLA-A2.1 stabilization at the cell surface was 
determined by flow cytometry using MAb BB7.2. The fluorescence 
index is expressed as the experimental mean fluorescence divided 
by the mean fluorescence that is obtained when T2 cells are 
incubated with an HLA-A2.1 non-binding peptide, WMAF- 
KERKV, at a similar concentration. Peptides: O—O, INF ma 
58-66; • —• ,  HIV pol 510-518; □ —Q  gplOO 154-162; 
gplOO 280-288; A—A, gplOO 457^66.
bearing potential self-rcactive TcR can emerge in the periph­
ery. They may have escaped from tolerance induction because 
they bear low-affinity TcR, whereas potential autoreactive 
CTL bearing high-affinity TcR are probably deleted in the 
thymus (Schwartz, 1989) or maybe tolerized in the periphery. 
The anti-tyrosinase CTL clones described by Wôlfel and 
colleagues and the gplOO 457-466-reactive TIL 1200 lympho­
cytes, exhibiting low peptide/MHC affinity, may have emerged 
from precursor T lymphocytes of this type. High-affinity
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autoreactive CTL may have escaped tolerance induction, 
because they have not encountered their antigenic peptide in 
the thymus or in the periphery. It is not clear how high- or 
intermediate-affinity CTL, like gplOO 280-288-reactive T lym­
phocytes (C o x e t a l 1994) or gplOO 154-162-reactive TIL 1200 
ymphocytes, can exist in the periphery as ignorant T lympho­
cytes without causing apparent autoimmune disease (Ohashi,
1994). A possible explanation is that HLA-A2.1-gpIOO 154-162/ 
280-288 complexes on normal melanocytes may be recognized 
by activated CTL, while being incapable of initiating primary 
immune responses in vivo. Apparently, in the case of mela­
noma, gplOO-reactive precursor T lymphocytes can be trig­
gered in vivo. This may be the result of a higher expression 
level of the gplOO antigen in melanoma cells. Alternatively, 
necrosis in melanoma tumors may lead to uptake and presenta­
tion of gplOO-derived peptides to T lymphocytes by profes­
sional antigen-presenting cells.
Clinical data, indicating that vitiligo (local depigmentation 
of the skin) is associated with improved survival of melanoma 
patients (Bystryn et al, 1987), suggest that these patients
benefit from an autoimmune response to melanocytes. In 
addition, re-infusion of TIL 1200 plus IL-2 into the autologous 
patient was accompanied by regression of metastatic tumor 
(Kawakami et a l ,  19946). This suggests that the generation of 
an immune response against the gplOO melanocyte differentia­
tion antigen may have anti-tumor effects in vivo. Therefore, the 
gplOO antigen, of which 3 distinct HLA-A2.1 presentable 
epitopes have already been identified, is an attractive target 
antigen in the development of immuno-therapeutic protocols 
against melanoma.
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